These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Comparison of the effects of novel vitamin D receptor analog VS-105 and paricalcitol on chronic kidney disease-mineral bone disorder in an experimental model of chronic kidney disease. Fujii H, Yonekura Y, Nakai K, Kono K, Goto S, Nishi S. J Steroid Biochem Mol Biol; 2017 Mar; 167():55-60. PubMed ID: 27818277 [Abstract] [Full Text] [Related]
3. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats. Meng Y, Zhang H, Li Y, Li Q, Zuo L. Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307 [Abstract] [Full Text] [Related]
7. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. Shalhoub V, Shatzen EM, Ward SC, Davis J, Stevens J, Bi V, Renshaw L, Hawkins N, Wang W, Chen C, Tsai MM, Cattley RC, Wronski TJ, Xia X, Li X, Henley C, Eschenberg M, Richards WG. J Clin Invest; 2012 Jul; 122(7):2543-53. PubMed ID: 22728934 [Abstract] [Full Text] [Related]
8. Effects of triangle grass decoction on bone metabolism in rats with chronic kidney disease complicated with mineral and bone abnormalities. Liu L, Wang L, Li L, Wang H, Yuan L, Kang L, Jiang Q, Chen G, Lv N, Cui X, Huang L, Wu H, Xu J, Li Y. J Ethnopharmacol; 2021 Jul 15; 275():114126. PubMed ID: 33872749 [Abstract] [Full Text] [Related]
9. Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats. Noonan W, Koch K, Nakane M, Ma J, Dixon D, Bolin A, Reinhart G. Nephrol Dial Transplant; 2008 Dec 15; 23(12):3824-30. PubMed ID: 18644798 [Abstract] [Full Text] [Related]
13. Relationship between aortic mineral elements and osteodystrophy in mice with chronic kidney disease. Matsumoto T, Fukushima S, Kanasaki T, Hagino S. Biol Trace Elem Res; 2012 Dec 15; 150(1-3):278-84. PubMed ID: 22700181 [Abstract] [Full Text] [Related]
14. [Diabetic Kidney Disease 3rd stage - laboratory markers of mineral bone disorder]. Klimentová A, Ságová I, Prídavková D, Kantárová D, Makovický P, Sadloňová J, Mokáň M. Vnitr Lek; 2016 Dec 15; 62(6):442-8. PubMed ID: 27485841 [Abstract] [Full Text] [Related]
15. A rat model of chronic kidney disease-mineral bone disorder. Moe SM, Chen NX, Seifert MF, Sinders RM, Duan D, Chen X, Liang Y, Radcliff JS, White KE, Gattone VH. Kidney Int; 2009 Jan 15; 75(2):176-84. PubMed ID: 18800026 [Abstract] [Full Text] [Related]
16. Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism. Yu L, Tomlinson JE, Alexander ST, Hensley K, Han CY, Dwyer D, Stolina M, Dean C, Goodman WG, Richards WG, Li X. Calcif Tissue Int; 2017 Dec 15; 101(6):641-653. PubMed ID: 29038882 [Abstract] [Full Text] [Related]
17. The intervention effect of zuogui pill on chronic kidney disease-mineral and bone disorder regulatory factor. Ma X, He L. Biomed Pharmacother; 2018 Oct 15; 106():54-60. PubMed ID: 29957466 [Abstract] [Full Text] [Related]
18. Inositol 1,4,5-trisphosphate receptor type 2 is associated with the bone-vessel axis in chronic kidney disease-mineral bone disorder. Xiao Q, Tang Y, Luo H, Chen S, Tang Q, Chen R, Xiong L, Xiao J, Hong D, Wang L, Li G, Li Y. Ren Fail; 2023 Dec 15; 45(1):2162419. PubMed ID: 36645057 [Abstract] [Full Text] [Related]